·综述·局部进展期结直肠癌新辅助免疫治疗临床研究及应用进展*陈顺①②仵朝晖①解有成①王俊科①梁昭君①李斌①综述于晓辉①审校摘要局部进展期结直肠癌术后高复发风险使得患者长期生存面临挑战。免疫检查点抑制剂的出现使得许多恶性肿瘤的治疗发生了革命性的转变。目前，免疫检查点抑制剂已被批准用于不可切除的结直肠癌晚期的一线治疗，但其在新辅助治疗中的疗效和安全性的描述尚不多见。早期的临床试验已经初步证实了新辅助免疫治疗在局部进展期结直肠癌患者中的临床益处，进一步高质量的临床试验正在开展。本文就免疫检查点抑制剂在局部进展期结直肠癌新辅助治疗中的相关临床研究和应用进展进行梳理和总结，以期为结直肠癌新辅助免疫治疗的发展提供一定的参考。关键词局部进展期结直肠癌免疫检查点抑制剂新辅助治疗临床试验doi:10.12354/j.issn.1000-8179.2023.20221215ClinicalresearchandapplicationprogressofneoadjuvantimmunotherapyinadvancedlocalcolorectalcancerShunChen1,2,ZhaohuiWu1,YouchengXie1,JunkeWang1,ZhaojunLiang1,BinLi1,XiaohuiYu1Correspondenceto:XiaohuiYu;E-mail:yuxiaohui528@126.com1DepartmentofGastroenterology,MedicalExperimentalCenterofthe940thHospitalofJointLogisticsSupportForceofPLA,KeyLaboratoryofStemCellsandGeneDrugsofGansuProvince,Lanzhou730050,China;2DepartmentofGastroenterology,LanzhouUni-versitySecondHospital,Lanzhou730050,ChinaThisworkwassupportedbyLanzhouTalentInnovationandEntrepreneurshipProject（No.2020RC111）andGansuClinicalMedicalRe-searchCenterforSevereDiseasesofDigestiveSystem（No.20JR10RA017）AbstractThehighriskofrecurrenceaftersurgeryforlocaladvancedcolorectalcancer(LACRC)makeslong-termsurvivalchallengingforpa-tients.Theadventofimmunecheckpointinhibitors(ICIs)hasrevolutionizedthetreatmentofmanymalignancies.Currently,ICIsareap-provedforfirst-linetreatmentofunresectableLACRC,buttheirefficacyandsafetyprofileinneoadjuvanttherapyarenotwelldescribed.EarlyclinicaltrialshavedemonstratedtheclinicalbenefitofneoadjuvantimmunotherapyinpatientswithLACRC,andlargeradvancedclinic-altrialsareunderway.ThisreviewsummarizesthefindingsofclinicalstudiesandapplicationsofICIsintheneoadjuvanttreatmentofLACRC,withthea...
